Mitochondria-targeted protective compounds in Parkinson's and Alzheimer's diseases

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Fernández Moriano, Carlos ^a   González Burgos, Elena ^a   Gómez Serranillos, M Pilar ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINETRIPHOSPHATE; CELL DEATH; CELL SIGNALING; DETOXIFICATION; DISEASES; MITOCHONDRIA; MOBILE SECURITY; SYNTHESIS (CHEMICAL);

ALZHEIMER'S DISEASE; APOPTOTIC SIGNALING; CALCIUM HOMEOSTASIS; CENTRAL NERVOUS SYSTEMS; MITOCHONDRIAL DYSFUNCTION; NEURODEGENERATIVE DISORDERS; PARKINSON'S DISEASE; THERAPEUTIC STRATEGY;

NEURODEGENERATIVE DISEASES;

ACTEOSIDE; ALKALOID; ALPHA SYNUCLEIN; AMPHETAMINE; CAFFEINE; COCAINE; DJ 1 PROTEIN; DOPAMINE; EPICATECHIN; EPIGALLOCATECHIN GALLATE; GLUTATHIONE; GYPENOSIDE 17; LEUCINE RICH REPEAT KINASE 2; MELATONIN; MESYLIC ACID DERIVATIVE; MITOQUINONE MESYLATE; NEUROTOXIN; PARKIN; PEROXIREDOXIN 3; PEROXIREDOXIN 6; PLANT GLYCOSIDE; PROTEIN SERINE THREONINE KINASE; RESVERATROL; THIOCTIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; PROTECTIVE AGENT;

ALZHEIMER DISEASE; ATP13A2 GENE; BRAIN TISSUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FAMILIAL DISEASE; GENE; GENE MUTATION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MITOCHONDRIA; PARKINSON DISEASE; PROTECTIVE AGENTS;

EID: 84929378587     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/408927     Document Type: Review

References (226)

1. L. C. Schenkel and M. Bakovic, "Formation and regulation of mitochondrial membranes," International Journal of Cell Biology, vol. 2014, Article ID 709828, 13 pages, 2014.
2. S. E. Horvath and G. Daum, "Lipids of mitochondria," Progress in Lipid Research, vol. 52, no. 4, pp. 590-614, 2013.
3. R. W. Taylor and D. M. Turnbull, "Mitochondrial DNA mutations in human disease," Nature Reviews Genetics, vol. 6, no. 5, pp. 389-402, 2005.
4. N. V. Dudkina, R. Kouril, K. Peters, H.-P. Braun, and E. J. Boekema, "Structure and function ofmitochondrial supercomplexes," Biochimica et BiophysicaActa, vol. 1797,no. 6-7, pp.664-670, 2010.
5. D. G. Brdiczka, D. B. Zorov, and S.-S. Sheu, "Mitochondrial contact sites: Their role in energy metabolism and apoptosis," Biochimica et Biophysica Acta, vol. 1762,no. 2, pp. 148-163, 2006.
6. L. J. Martin, "Biology of mitochondria in neurodegenerative diseases," Progress in Molecular Biology and Translational Science, vol. 107, pp. 355-415, 2012.
7. M. T. Lin and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases," Nature, vol. 443, no. 7113, pp. 787-795, 2006.
8. J. M. Beitz, "Parkinson's disease: A review," Frontiers in Bioscience, vol. 6, pp. 65-74, 2014.
9. J. M. Shulman, P. L. De Jager, andM. B. Feany, "Parkinson's disease: Genetics and pathogenesis," Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 193-222, 2011.
10. J. Parkinson, "An essay on the shaking palsy," The Journal of neuropsychiatry and clinical neurosciences, vol. 14,no. 2, pp. 223-236, 2002.
11. T. Pringsheim, N. Jette, A. Frolkis, and T. D. Steeves, "The prevalence of Parkinson's disease: A systematic reviewandmetaanalysis," Movement Disorders, vol. 29, no. 13, pp. 1583-1590, 2014.
12. A. Wright Willis, B. A. Evanoff, M. Lian, S. R. Criswell, and B. A. Racette, "Geographic and ethnic variation in Parkinson disease: A population-based study of us medicare beneficiaries," Neuroepidemiology, vol. 34, no. 3, pp. 143-151, 2010.
13. B. C. L. Lai and J. K. C. Tsui, "Epidemiology of Parkinson's disease," British Columbia Medical Journal, vol. 43, no. 3, pp. 133-137, 2001.
14. B. R.Thanvi, S. K. Munshi, N. Vijaykumar, and T. C. N. Lo, "Neuropsychiatric non-motor aspects of Parkinson's disease," PostgraduateMedical Journal, vol. 79,no. 936, pp. 561-565, 2003.
15. S. Gandhi and N. W. Wood, "Genome-wide association studies: The key to unlocking neurodegeneration?" Nature Neuroscience, vol. 13, no. 7, pp. 789-794, 2010.
16. K. Kieburtz and K. B. Wunderle, "Parkinson's disease: Evidence for environmental risk factors," MovementDisorders, vol. 28,no. 1, pp. 8-13, 2013.
17. H. Kim, "Alpha-synuclein expression in patients with Parkinson's disease: A clinician's perspective," Experimental Neurobiology, vol. 22, no. 2, pp. 77-83, 2013.
18. S. Veeriah, B. S. Taylor, S.Meng et al., "Somaticmutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies," Nature Genetics, vol. 42, no. 1, pp. 77-82, 2010.
19. B. Björkblom, A. Adilbayeva, J. Maple-Grødem et al., "Parkinson disease protein DJ-1 binds metals and protects against metal-induced cytotoxicity," Journal of Biological Chemistry, vol. 288, no. 31, pp. 22809-22820, 2013.
20. V. A. Morais, P. Verstreken, A. Roethig et al., "Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function," EMBO Molecular Medicine, vol. 1, no. 2, pp. 99-111, 2009.
21. N. L. Khan, S. Jain, J. M. Lynch et al., "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: Clinical, pathological, olfactory and functional imaging and genetic data," Brain, vol. 128, no. 12, pp. 2786-2796, 2005.
22. A. Moretto and C. Colosio, "The role of pesticide exposure in the genesis of Parkinson's disease: Epidemiological studies and experimental data," Toxicology, vol. 307, pp. 24-34, 2013.
23. A. G. Fitzmaurice, S. L. Rhodes,M. Cockburn, B. Ritz, and J. M. Bronstein, "Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease," Neurology, vol. 82, no. 5, pp. 419-426, 2014.
24. K. M. Powers, T. Smith-Weller, G. M. Franklin,W. T. Longstreth Jr., P. D. Swanson, and H. Checkoway, "Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes," Neurology, vol. 60, no. 11, pp. 1761-1766, 2003.
25. X.Gao,H. Chen, T. T. Fung et al., "Prospective study of dietary pattern and risk of Parkinson disease," The American Journal of Clinical Nutrition, vol. 86, no. 5, pp. 1486-1494, 2007.
26. X. Yang and Y. Xu, "Mutations in the ATP13A2 gene and parkinsonism: A preliminary review," BioMed Research International, vol. 2014, Article ID371256, 9 pages, 2014.
27. D. R. Williams, A. Hadeed, A. S. NajimAl-Din, A.-L. Wreikat, and A. J. Lees, "Kufor Rakeb disease: Autosomal recessive, levodopa-responsive Parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia," Movement Disorders, vol. 20, no. 10, pp. 1264-1271, 2005.
28. A. Ramirez, A. Heimbach, J. Gründemann et al., "Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase," Nature Genetics, vol. 38, no. 10, pp. 1184-1191, 2006.
29. X. Wang, T. G. Petrie, Y. Liu, J. Liu, H. Fujioka, and X. Zhu, "Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction," Journal of Neurochemistry, vol. 121, no. 5, pp. 830-839, 2012.
30. M. W. Dodson andM. Guo, "Pink1, Parkin, DJ-1 andmitochondrial dysfunction in Parkinson's disease," Current Opinion in Neurobiology, vol. 17, no. 3, pp. 331-337, 2007.
31. K. E. Morrison, "Parkin mutations and early onset parkinsonism," Brain, vol. 126, no. 6, pp. 1250-1251, 2003.
32. J.-Y. Lee, Y. Nagano, J. P. Taylor, K. L. Lim, and T.-P. Yao, "Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy," The Journal of Cell Biology, vol. 189, no. 4, pp. 671-679, 2010.
33. S. Song, S. Jang, J. Park et al., "Characterization of PINK1 (PTEN-induced putative kinase 1) mutations associated with Parkinson disease in mammalian cells and drosophila," The Journal of Biological Chemistry, vol. 288, no. 8, pp. 5660-5672, 2013.
34. A. Kazlauskaite and M. M. Muqit, "PINK1 and Parkin-mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease," FEBS Journal, vol. 282, no. 2, pp. 215-223, 2015.
35. H. A. Lashuel, B. M. Petre, J. Wall et al., "α-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils," Journal of Molecular Biology, vol. 322, no. 5, pp. 1089-1102, 2002.
36. L. Stefanis, "α-Synuclein in Parkinson's disease," Cold Spring Harbor Perspectives in Medicine, vol. 2, no.2,Article IDa009399, 2012.
37. J. Q. Li, L. Tan, and J. T. Yu, "The role of the LRRK2 gene in Parkinsonism," Molecular Neurodegeneration, vol. 9, article 47, 2014.
38. I. F. Mata, W. J. Wedemeyer, M. J. Farrer, J. P. Taylor, and K. A. Gallo, "LRRK2 in Parkinson's disease: Protein domains and functional insights," Trends in Neurosciences, vol. 29, no. 5, pp. 286-293, 2006.
39. C. Henchcliffe and M. F. Beal, "Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis," Nature Clinical Practice Neurology, vol. 4, no. 11, pp. 600-609, 2008.
40. S. R. Subramaniam and M.-F. Chesselet, "Mitochondrial dysfunction and oxidative stress in Parkinson's disease," Progress in Neurobiology, vol. 106-107, pp. 17-32, 2013.
41. D. N. Hauser and T. G. Hastings, "Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism," Neurobiology of Disease, vol. 51, pp. 35-42, 2013.
42. D. Ebrahimi-Fakhari, L. Wahlster, and P. J. McLean, "Protein degradation pathways in Parkinson's disease: Curse or blessing," Acta Neuropathologica, vol. 124, no. 2, pp. 153-172, 2012.
43. A. Bir, O. Sen, S. Anand et al., "α-synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: Implications in the pathogenesis of Parkinson's disease," Journal of Neurochemistry, vol. 131, no. 6, pp. 868-877, 2014.
44. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, "Chronic parkinsonism in humans due to a product of meperidineanalog synthesis," Science, vol. 219, no. 4587, pp. 979-980, 1983.
45. A.H.V. Schapira, J. M. Cooper,D.Dexter, J. B. Clark, P. Jenner, and C. D. Marsden, "Mitochondrial complex I deficiency in Parkinson's disease," Journal of Neurochemistry, vol. 54, no. 3, pp. 823-827, 1990.
46. V. Dias, E. Junn, and M. M. Mouradian, "The role of oxidative stress in Parkinson's disease," Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461-491, 2013.
47. R. H. Haas, F. Nasirian, K. Nakano et al., "Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease," Annals of Neurology, vol. 37, no. 6, pp. 714-722, 1995.
48. M. Rana, I. de Coo, F. Diaz, H. Smeets, and C. T.Moraes, "An out-of-frame cytochrome b gene deletion from a patient with parkinsonism is associated with impaired complex III assembly and an increase in free radical production," Annals of Neurology, vol. 48, no. 5, pp. 774-781, 2000.
49. A. C. Rego and C. R. Oliveira, "Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: Implications for the pathogenesis of neurodegenerative diseases," Neurochemical Research, vol. 28, no. 10, pp. 1563-1574, 2003.
50. S. L. Budd, L. Tenneti, T. Lishnak, and S. A. Lipton, "Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 11, pp. 6161-6166, 2000.
51. M. R. Gluck and G. D. Zeevalk, "Inhibition of brain mitochondrial respiration by dopamine and its metabolites: Implications for Parkinson's disease and catecholamine-associated diseases," Journal of Neurochemistry, vol. 91, no. 4, pp. 788-795, 2004.
52. F. H. Khan, T. Sen, A. K. Maiti, S. Jana, U. Chatterjee, and S. Chakrabarti, "Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: Implications for Parkinson's disease," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1741, no. 1-2, pp. 65-74, 2005.
53. S. Jana,M. Sinha, D. Chanda et al., "Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease," Biochimica et Biophysica Acta, vol. 1812, no. 6, pp. 663-673, 2011.
54. V. S. Van Laar, A. J. Mishizen, M. Cascio, and T. G. Hastings, "Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells," Neurobiology of Disease, vol. 34, no. 3, pp. 487-500, 2009.
55. T. G. Hastings, "The role of dopamine oxidation in mitochondrial dysfunction: Implications for Parkinson's disease," Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 469-472, 2009.
56. S. B. Berman and T. G. Hastings, "Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease," Journal of Neurochemistry, vol. 73, no. 3, pp. 1127-1137, 1999.
57. Y. Luo, H. Umegaki, X. Wang, R. Abe, and G. S. Roth, "Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway," The Journal of Biological Chemistry, vol. 273, no. 6, pp. 3756-3764, 1998.
58. H. J. Choi, S. Y. Lee, Y. Cho, H. No, S. W. Kim, and O. Hwang, "Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease," Neurochemistry International, vol. 48, no. 4, pp. 255-262, 2008.
59. T.E.Gunter, L. Buntinas,G. Sparagna, R. Eliseev, andK.Gunter, "Mitochondrial calciumtransport:mechanisms and functions," Cell Calcium, vol. 28, no. 5-6, pp. 285-296, 2000.
60. N. B. Pivovarova and S. B. Andrews, "Calcium-dependentmitochondrial function and dysfunction in neurons: Minireview," The FEBS Journal, vol. 277, no. 18, pp. 3622-3636, 2010.
61. J. P. Sheehan, R. H. Swerdlow, W. D. Parker, S. W. Miller, R. E. Davis, and J. B. Tuttle, "Altered calcium homeostasis in cells transformed bymitochondria fromindividualswith Parkinson's disease," Journal of Neurochemistry, vol. 68, no. 3, pp. 1221-1233, 1997.
62. J. Park, Y. Kim, and J. Chung, "Mitochondrial dysfunction and Parkinson's disease genes: Insights from Drosophila," Disease Models & Mechanisms, vol. 2, no. 7-8, pp. 336-340, 2009.
63. W. Mandemakers, V. A. Morais, and B. de Strooper, "A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases," Journal of Cell Science, vol. 120, no. 10, pp. 1707-1716, 2007.
64. P. P.Hien,H.Gortnizka, and R. Kraemer, "Rotenone-potential and prospect for sustainable agriculture," Omonrice, vol. 11, pp. 83-92, 2003.
65. A. B.Manning-Bog, A. L.McCormack, J. Li,V.N.Uversky, A. L. Fink, and D. A. Di Monte, "The herbicide paraquat causes upregulation and aggregation of α-synuclein in mice: Paraquat and α-synuclein,"The Journal of Biological Chemistry, vol. 277, no. 3, pp. 1641-1644, 2002.
66. N. Simola, M. Morelli, and A. R. Carta, "The 6-hydroxydopamine model of Parkinson's disease," Neurotoxicity Research, vol. 11, no. 3-4, pp. 151-167, 2007.
67. G. Patki and Y.-S. Lau, "Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease," Pharmacology Biochemistry and Behavior, vol. 99, no. 4, pp. 704-711, 2011.
68. K. S. Saravanan, K. M. Sindhu, and K. P. Mohanakumar, "Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model," Journal of Pineal Research, vol. 42, no. 3, pp. 247-253, 2007.
69. S. C. Sousa and R. F. Castilho, "Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death," Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1110-1116, 2005.
70. F. Dabbeni-Sala, S. di Santo, D. Franceschini, S. D. Skaper, and P. Giusti, "Melatonin protects against 6-OHDA-induced neurotoxicity in rats: A role for mitochondrial complex I activity," Federation of American Societies for Experimental Biology Journal, vol. 15, no. 1, pp. 164-170, 2001.
71. E. Absi, A. Ayala, A. Machado, and J. Parrado, "Protective effect of melatonin against the 1-methyl-4-phenylpyridiniuminduced inhibition of complex I of the mitochondrial respiratory chain," Journal of Pineal Research, vol. 29, no. 1, pp. 40-47, 2000.
72. P. Mao, C. K. Meshul, P.Thuillier, N. R. S. Goldberg, and P. H. Reddy, "CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria," PLoS ONE, vol. 7, no. 1, Article ID e29343, 2012.
73. M. E. Solesio, T. A. Prime, A. Logan et al., "The mitochondriatargeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1832, no. 1, pp. 174-182, 2013.
74. H. S. Chun and W. C. Low, "Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells," Toxicology, vol. 292, no. 2-3, pp. 105-112, 2012.
75. D.-W. Li, G.-R. Li, Y. Lu et al., "α-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation," International Journal of Molecular Medicine, vol. 32, no. 1, pp. 108-114, 2013.
76. A. A. Abdin and N. I. Sarhan, "Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity," Neuroscience Research, vol. 71, no. 4, pp. 387-395, 2011.
77. H. Zhang, H. Jia, J. Liu et al., "Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease," Journal of Cellular and Molecular Medicine, vol. 14, no. 1-2, pp. 215-225, 2010.
78. S. Bharath, B. C. Cochran, M. Hsu, J. Liu, B. N. Ames, and J. K. Andersen, "Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: Implications for Parkinson's disease therapy," NeuroToxicology, vol. 23, no. 4-5, pp. 479-486, 2002.
79. X. Wang, E. Perez, R. Liu, L. J. Yan, R. T. Mallet, and S. H. Yang, "Pyruvate protects mitochondria from oxidative stress in human neuroblastomaSK-N-SHcells," Brain Research, vol. 1132, no. 1, pp. 1-9, 2007.
80. L.-Z. Wang,W.-C. Sun, and X.-Z. Zhu, "Ethyl pyruvate protects PC12 cells from dopamine-induced apoptosis," European Journal of Pharmacology, vol. 508, no. 1-3, pp. 57-68, 2005.
81. C. Lu, J. Zhang, X. Shi et al., "Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP," International Journal of Biological Sciences, vol. 10, no. 4, pp. 350-357, 2014.
82. Y.-H. Wang, H.-T. Yu, X.-P. Pu, and G.-H. Du, "Baicalein prevents 6-hydroxydopamine-induced mitochondrial dysfunction in SH-SY5Y cells via inhibition of mitochondrial oxidation and up-regulation of DJ-1 protein expression,"Molecules, vol. 18, no. 12, pp. 14726-14738, 2013.
83. X.-X. Li, G.-R. He, X. Mu et al., "Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria," European Journal of Pharmacology, vol. 674, no. 2-3, pp. 227-233, 2012.
84. H. J. Lee, Y. H. Noh, D. Y. Lee et al., "Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells," European Journal of Cell Biology, vol. 84, no. 11, pp. 897-905, 2005.
85. R. Barros Silva, N. A. G. Santos, N. M. Martins et al., "Caffeic acid phenethyl ester protects against the dopaminergic neuronal loss induced by 6-hydroxydopamine in rats," Neuroscience, vol. 233, pp. 86-94, 2013.
86. C. Noelker, M. Bacher, P. Gocke et al., "The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity," Neuroscience Letters, vol. 383, no. 1-2, pp. 39-43, 2005.
87. R. L. Jayaraj, N. Elangovan, K. Manigandan, S. Singh, and S. Shukla, "CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease," BioMed Research International, vol. 2014, Article ID 236182, 11 pages, 2014.
88. R. L. Jayaraj, K. Tamilselvam, T. Manivasagam, and N. Elangovan, "Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of parkinson's disease," Journal of Molecular Neuroscience, vol. 51, no. 3, pp. 863-870, 2013.
89. Z. Liu, Y. Yu, X. Li, C. A. Ross, and W. W. Smith, "Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism," Pharmacological Research, vol. 63, no. 5, pp. 439-444, 2011.
90. B. Jagatha, R. B. Mythri, S. Vali, and M. M. S. Bharath, "Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies," Free Radical Biology and Medicine, vol. 44, no. 5, pp. 907-917, 2008.
91. J.-Z. Huang, Y.-Z. Chen, M. Su et al., "Dl-3-n-Butylphthalide prevents oxidative damage and reduces mitochondrial dysfunction in an MPP+-induced cellular model of Parkinson's disease," Neuroscience Letters, vol. 475, no. 2, pp. 89-94, 2010.
92. R. Kuang, Y. Sun, W. Yuan, L. Lei, and X. Zheng, "Protective effects of echinacoside, one of the phenylethanoid glycosides, onH2O2-induced cytotoxicity in PC12 cells," PlantaMedica, vol. 75, no. 14, pp. 1499-1504, 2009.
93. N.Xiong, J.Xiong,G.Khare et al., "Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease," PLoS ONE, vol. 6, no. 6,Article ID e20677, 11 pages, 2011.
94. S. R. Subramaniam and E. M. Ellis, "Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease," Journal of Neuroscience Research, vol. 91,no. 3, pp. 453-461, 2013.
95. K. H. Kim, K. Song, S. H. Yoon, O. Shehzad, Y. S. Kim, and J. H. Son, "Rescue of PINK1 protein null-specific mitochondrial complex IV deficits by ginsenoside Re activation of nitric oxide signaling,"The Journal of Biological Chemistry, vol. 287, no. 53, pp. 44109-44120, 2012.
96. R. B. Mythri, G. Harish, S. K. Dubey, K. Misra, and M. M. Srinivas Bharath, "Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitritemediated nitrosative stress and damage of brain mitochondria in vitro: Implications for Parkinson's disease," Molecular and Cellular Biochemistry, vol. 347, no. 1-2, pp. 135-143, 2011.
97. Y. Han, J. Kim, J. Cho, C. S. Lee, and D. Kim, "Comparison of the protective effect of indole α-carbolines and R-(-)-deprenyl against nitrogen Species-induced cell death in experimental culture model of parkinson's disease," Journal of Clinical Neurology, vol. 1, no. 1, pp. 81-91, 2005.
98. K. Tamilselvam, N. Braidy, T. Manivasagam et al., "Neuroprotective effects of hesperidin, a plant flavanone, on rotenoneinduced oxidative stress and apoptosis in a cellular model for Parkinson's disease," OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID102741, 11 pages, 2013.
99. L.-L. Tian, Z. Zhou, Q. Zhang et al., "Protective effect of (+/-) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells," Cellular Physiology and Biochemistry, vol. 20, no. 6, pp. 1019-1032, 2007.
100. G. Filomeni, I. Graziani, D. de Zio et al., "Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: Possible implications for Parkinson's disease," Neurobiology of Aging, vol. 33, no. 4, pp. 767-785, 2012.
101. F. Yi, X. He, and D. Wang, "Lycopene protects against MPP+- induced cytotoxicity by maintaining mitochondrial function in SH-SY5Y cells," Neurochemical Research, vol. 38,no. 8, pp. 1747-1757, 2013.
102. H. Kaur, S. Chauhan, and R. Sandhir, "Protective effect of lycopene on oxidative stress and cognitive decline in rotenone inducedmodel of Parkinson's disease," Neurochemical Research, vol. 36, no. 8, pp. 1435-1443, 2011.
103. M. B. Bagh, A. K. Maiti, S. Jana, K. Banerjee, A. Roy, and S. Chakrabarti, "Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: Implications in the neuroprotective therapy of Parkinson's disease," Free Radical Research, vol. 42, no. 6, pp. 574-581, 2008.
104. W.-B.Liu, J.Zhou, Y.Quet al., "Neuroprotective effectofosthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production," Neurochemistry International, vol. 57, no. 3, pp. 206-215, 2010.
105. P. Shrivastava, K. Vaibhav, R. Tabassum et al., "Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model," Journal of Nutritional Biochemistry, vol. 24, no. 4, pp. 680-687, 2013.
106. X. Cai, H. Jia, Z. Liu et al., "Polyhydroxylated fullerene derivative C60(OH)24 prevents mitochondrial dysfunction and oxidative damage in an MPP+-induced cellular model of Parkinson's disease," Journal of Neuroscience Research, vol. 86, no. 16, pp. 3622-3634, 2008.
107. S. Guan, B. Jiang, Y. M. Bao, and L. J. An, "Protocatechuic acid suppressesMPP+-induced mitochondrial dysfunction and apoptotic cell death in PC12 cells," Food and Chemical Toxicology, vol. 44, no. 10, pp. 1659-1666, 2006.
108. S. S. Karuppagounder, S. K. Madathil, M. Pandey, R. Haobam, U. Rajamma, and K. P.Mohanakumar, "Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats," Neuroscience, vol. 236, pp. 136-148, 2013.
109. J. Bournival, M. Plouffe, J. Renaud, C. Provencher, and M.- G. Martinoli, "Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system," Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 921941, 11 pages, 2012.
110. J. Jiang, J. Jiang, Y. Zuo, and Z. Gu, "Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease," International Journal ofMolecular Medicine, vol. 31, no. 4, pp. 825-832, 2013.
111. A. Ferretta, A. Gaballo, P. Tanzarella et al., "Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1842, no. 7, pp. 902-915, 2014.
112. P. Ren, H. Jiang, R. Li et al., "Rosmarinic acid inhibits 6- OHDA-induced neurotoxicity by anti-oxidation in MES23.5 cells," Journal ofMolecularNeuroscience, vol. 39,no. 1-2, pp. 220-225, 2009.
113. X.-J. Wang and J.-X. Xu, "Salvianic acid A protects human neuroblastoma SH-SY5Y cells againstMPP+-induced cytotoxicity," Neuroscience Research, vol. 51, no. 2, pp. 129-138, 2005.
114. L.-L. Tian, X.-J. Wang, Y.-N. Sun et al., "Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents 6-hydroxydopamine induced apoptosis in SH-SY5Y cells," International Journal of Biochemistry & Cell Biology, vol. 40, no. 3, pp. 409-422, 2008.
115. D.-H. Lee, C.-S.Kim, and Y. J. Lee, "Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro," Food and Chemical Toxicology, vol. 49, no. 1, pp. 271-280, 2011.
116. P.Dewapriya, S. W. A.Himaya, Y.-X. Li, and S.-K. Kim, "Tyrosol exerts a protective effect against dopaminergic neuronal cell death in in vitro model of Parkinson's disease," Food Chemistry, vol. 141, no. 2, pp. 1147-1157, 2013.
117. X.-L. Lu,X.-L. Yao, Z. Liuet al., "Protective effects of xyloketalB againstMPP+-induced neurotoxicity in Caenorhabditis elegans and PC12 cells," Brain Research, vol. 1332, pp. 110-119, 2010.
118. K. E. Strathearn, G. G. Yousef, M. H. Grace et al., "Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson's disease," Brain Research, vol. 1555, pp. 60-77, 2014.
119. M. Geed, D. Garabadu, A. Ahmad, and S. Krishnamurthy, "Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats," Pharmacology Biochemistry & Behavior, vol. 117, pp. 92-103, 2014.
120. S. Guo, E. Bezard, and B. Zhao, "Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway," Free Radical Biology and Medicine, vol. 39, no. 5, pp. 682-695, 2005.
121. C. K. Hwang and H. S. Chun, "Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamineinduced apoptosis in dopaminergic neurons," Bioscience, Biotechnology and Biochemistry, vol. 76, no. 3, pp. 536-543, 2012.
122. S.Hu, R.Han, S.Mak, and Y.Han, "Protection against 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis by water extract of ginseng (Panax ginseng C.A. Meyer) in SH-SY5Y cells," Journal of Ethnopharmacology, vol. 135, no. 1, pp. 34-42, 2011.
123. H. G. Kim, M. S. Ju, D.-H. Kim et al., "Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of parkinson's disease," Basic & Clinical Pharmacology & Toxicology, vol. 107, no. 6, pp. 958-964, 2010.
124. H. Hampel, D. Prvulovic, S. Teipel et al., "The future of Alzheimer's disease: The next 10 years," Progress in Neurobiology, vol. 95, no. 4, pp. 718-728, 2011.
125. D. J. Selkoe and P. J. Lansbury, "Alzheimer's disease is the most common neurodegenerative disorder," in Basic Neurochemistry: Molecular, Cellular andMedical Aspects, J. G. Siegel, B. W. Agranoff, R. W. Albers et al., Eds., Lippincott-Raven, Philadelphia, Pa, USA, 6th edition, 1999.
126. Alzheimer'sAssociation, "Alzheimer's disease: Facts and figures," Alzheimer's & Dementia, vol. 9, no. 2, 2013.
127. C. W. Zhu and M. Sano, "Economic considerations in the management of Alzheimer's disease," Clinical Interventions in Aging, vol. 1, no. 2, pp. 143-154, 2006.
128. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M. Arrighi, "Forecasting the global burden of Alzheimer's disease," Alzheimer's & Dementia, vol. 3, no. 3, pp. 186-191, 2007.
129. D. J. Selkoe, "Alzheimer's disease: Genes, proteins, and therapy," Physiological Reviews, vol. 81, no. 2, pp. 741-766, 2001.
130. M. P. Mattson, "Pathways towards and away from Alzheimer's disease," Nature, vol. 430, no. 7000, pp. 631-639, 2004.
131. J. P. Blass and G. E. Gibson, "Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans," Journal of Alzheimer's Disease, vol. 9, no. 2, pp. 207-218, 2006.
132. A. Serrano-Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, "Neuropathological alterations in Alzheimer disease," Cold Spring Harbor Perspectives in Medicine, vol. 1, no. 1, Article ID a006189, 2011.
133. S. Jiang, Y. Li, C. Zhang et al., "M1 muscarinic acetylcholine receptor in Alzheimer's disease," Neuroscience Bulletin, vol. 30, no. 2, pp. 295-307, 2014.
134. R. N. Kalaria, G. E. Maestre, R. Arizaga et al., "Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors," The Lancet Neurology, vol. 7, no. 9, pp. 812-826, 2008.
135. R. E. Tanzi, "A brief history of Alzheimer's disease gene discovery," Journal of Alzheimer's Disease, vol. 33, supplement 1, pp. S5-S13, 2013.
136. Q. Zhou, D. T. Peng, X. R. Yuan et al., "APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease," Neural Regeneration Research, vol. 9, no. 6, pp. 653-660, 2014.
137. J. C. de la Torre, "Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics," The Lancet Neurology, vol. 3, no. 3, pp. 184-190, 2004.
138. Y. Feng and X. Wang, "Antioxidant therapies for Alzheimer's disease," Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 472932, 17 pages, 2012.
139. M. H. Yana, X. Wang, and X. Zhu, "Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease," Free Radical Biology and Medicine, vol. 62, pp. 90-101, 2013.
140. X.Huang, C. S. Atwood,M. A.Hartshornet al., "TheAα peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction," Biochemistry, vol. 38, no. 24, pp. 7609-7616, 1999.
141. G. Perry, A. D. Cash, and M. A. Smith, "Alzheimer disease and oxidative stress," Journal of Biomedicine and Biotechnology, vol. 2, no. 3, pp. 120-123, 2002.
142. A. Huber, G. Stuchbury, A. Bürkle, J. Burnell, and G. Münch, "Neuroprotective therapies for Alzheimer's disease," Current Pharmaceutical Design, vol. 12, no. 6, pp. 705-717, 2006.
143. D. J. Bonda, H.-P. Lee, H.-G. Lee et al., "Novel therapeutics for Alzheimer's disease: An update," Current Opinion in Drug Discovery & Development, vol. 13, no. 2, pp. 235-246, 2010.
144. R.H. Swerdlow, "The neurodegenerative mitochondriopathies," Journal of Alzheimer's Disease, vol. 17, no. 4, pp. 737-751, 2009.
145. A. Maruszak and C. Zekanowski, "Mitochondrial dysfunction and Alzheimer's disease," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 320-330, 2011.
146. T. Vargas, C. Ugalde, C. Spuch et al., "Aα accumulation in choroid plexus is associated withmitochondrial-induced apoptosis," Neurobiology of Aging, vol. 31, no. 9, pp. 1569-1581, 2010.
147. S.Hauptmann, I. Scherping, S. Dröse et al., "Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice," Neurobiology of Aging, vol. 30, no. 10, pp. 1574-1586, 2009.
148. Y. G. Kaminsky, L. A. Tikhonova, and E. A. Kosenko, "Critical analysis of Alzheimer's amyloid-beta toxicity to mitochondria," Frontiers in Bioscience, vol. 20, pp. 173-197, 2015.
149. S. M. Cardoso, S. Santos, R. H. Swerdlow, and C. R. Oliveira, "Functional mitochondria are required for amyloid betamediated neurotoxicity," The FASEB Journal, vol. 15, no. 8, pp. 1439-1441, 2001.
150. C. Pereira, M. S. Santos, and C. Oliveira, "Mitochondrial function impairment induced by amyloid α-peptide on PC12 cells," NeuroReport, vol. 9, no. 8, pp. 1749-1755, 1998.
151. L. Canevari, J. B. Clark, and T. E. Bates, "α-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria," FEBS Letters, vol. 457, no. 1, pp. 131-134, 1999.
152. P. H. Reddy, S. McWeeney, B. S. Park et al., "Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease," Human Molecular Genetics, vol. 13, no. 12, pp. 1225-1240, 2004.
153. P. Picone, D. Nuzzo, L. Caruana, V. Scafidi, and M. Di Carlo, "Mitochondrial dysfunction: Different routes to Alzheimer's disease therapy," OxidativeMedicine and Cellular Longevity, vol. 2014, Article ID780179, 11 pages, 2014.
154. M. Manczak, T. S. Anekonda, E. Henson, B. S. Park, J. Quinn, and P. H. Reddy, "Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression," HumanMolecular Genetics, vol. 15,no. 9, pp. 1437-1449, 2006.
155. L. Devi, B. M. Prabhu, D. F. Galati, N. G. Avadhani, and H. K. Anandatheerthavarada, "Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction," Journal of Neuroscience, vol. 26, no. 35, pp. 9057-9068, 2006.
156. M.-Y. Cha, S.-H. Han, S. M. Son et al., "Mitochondria-specific accumulation of amyloid α induces mitochondrial dysfunction leading to apoptotic cell death," PLoS ONE, vol. 7, no. 4,Article ID e34929, 2012.
157. W. K. Hong, E. H. Han, D. G. Kim, J. Y. Ahn, J. S. Park, and B. G. Han, "Amyloid-α-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits," Neurochemical Research, vol. 32, no. 9, pp. 1483-1488, 2007.
158. E. M. Mutisya, A. C. Bowling, and M. F. Beal, "Cortical cytochrome oxidase activity is reduced in Alzheimer's disease," Journal of Neurochemistry, vol. 63, no. 6, pp. 2179-2184, 1994.
159. H. Atamna and R. Kumar, "Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase," Journal of Alzheimer's Disease, vol. 20, no. 1, supplement 2, pp. S439-S452, 2010.
160. G. S. Zubenko and P. Sauer, "SOD-1 activity and platelet membrane fluidity in Alzheimer's disease," Biological Psychiatry, vol. 25, no. 6, pp. 671-678, 1989.
161. P. I. Moreira, M. S. Santos, C. Sena, E. Nunes, R. Seiça, and C. R. Oliveira, "CoQ10 therapy attenuates amyloid beta-peptide toxicity in brainmitochondria isolated fromaged diabetic rats," Experimental Neurology, vol. 196, no. 1, pp. 112-119, 2005.
162. P. H. Reddy, R. Tripathi, Q. Troung et al., "Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics," Biochimica et Biophysica Acta- Molecular Basis of Disease, vol. 1822, no. 5, pp. 639-649, 2012.
163. X. Wang, B. Su, H.-G. Lee et al., "Impaired balance of mitochondrial fission and fusion in Alzheimer's disease," Journal of Neuroscience, vol. 29, no. 28, pp. 9090-9103, 2009.
164. J. G. Begley, W. Duan, S. Chan, K. Duff, and M. P. Mattson, "Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1mutant mice," Journal of Neurochemistry, vol. 72, no. 3, pp. 1030-1039, 1999.
165. M. Obulesu and M. J. Lakshmi, "Apoptosis in Alzheimer's disease: An understanding of the physiology, pathology and therapeutic avenues," Neurochemical Research, vol. 39,no. 12,pp. 2301-2312, 2014.
166. A. Eckert,U. Keil, C.A.Marques et al., "Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease," Biochemical Pharmacology, vol. 66, no. 8, pp. 1627-1634, 2003.
167. J. Götz and L. M. Ittner, "Animal models of Alzheimer's disease and frontotemporal dementia," Nature Reviews Neuroscience, vol. 9, no. 7, pp. 532-544, 2008.
168. Z. Feng, C. Qin, Y. Chang, and J.-T. Zhang, "Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease," Free Radical Biology and Medicine, vol. 40, no. 1, pp. 101-109, 2006.
169. N. Dragicevic, V. Delic, C. Cao et al., "Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells," Neuropharmacology, vol. 63, no. 8, pp. 1368-1379, 2012.
170. N. Dragicevic, N. Copes, G. O'Neal-Moffitt et al., "Melatonin treatment restoresmitochondrial function in Alzheimer's mice: A mitochondrial protective role of melatonin membrane receptor signaling," Journal of Pineal Research, vol. 51,no. 1, pp. 75-86, 2011.
171. M. J. McManus, M. P. Murphy, and J. L. Franklin, "The mitochondria-targeted antioxidant mitoq prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease," Journal of Neuroscience, vol. 31, no. 44, pp. 15703-15715, 2011.
172. S. Sanz-Blasco, R. A. Valero, I.Rodríguez-Crespo, C. Villalobos, and L. Núñez, "Mitochondrial Ca2+ overload underlies Aα oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs," PLoS ONE, vol. 3, no. 7,Article ID e2718, 2008.
173. Y. Yan, K. Gong, T. Ma et al., "Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells," Neuroscience Letters, vol. 531, no. 2, pp. 160-165, 2012.
174. X. Gan, S. Huang, L. Wu et al., "Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1842,no. 2, pp. 220-231, 2014.
175. J. Liu and B. N. Ames, "Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease," Nutritional Neuroscience, vol. 8, no. 2, pp. 67-89, 2005.
176. P. H. Reddy, "Role of mitochondria in neurodegenerative diseases: Mitochondria as a therapeutic target in Alzheimer's disease," CNS Spectrums, vol. 14, no. 8, supplement 7, pp. 6-13, 2009.
177. H. Du and S. S. Yan, "Mitochondrial medicine for neurodegenerative diseases," International Journal of Biochemistry and Cell Biology, vol. 42, no. 5, pp. 560-572, 2010.
178. P. I.Moreira, X. Zhu, X. Wang et al., "Mitochondria: A therapeutic target in neurodegeneration," Biochimica et Biophysica Acta, vol. 1802, no. 1, pp. 212-220, 2010.
179. M. Raukas, R. Rebane, R. Mahlapuu et al., "Mitochondrial oxidative stress index, activity of redox-sensitive aconitase and effects of endogenous anti- and pro-oxidants on its activity in control, Alzheimer's disease and Swedish Familial Alzheimer's disease brain," Free Radical Research, vol. 46, no. 12, pp. 1490-1495, 2012.
180. G. Aliev, J. Liu, J. C. Shenk et al., "Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats," Journal of Cellular and Molecular Medicine, vol. 13, no. 2, pp. 320-333, 2009.
181. H. Wang, Y. Xu, J. Yan et al., "Acteoside protects human neuroblastoma SH-SY5Y cells against α-amyloid-induced cell injury," Brain Research, vol. 1283, pp. 139-147, 2009.
182. I. Bolea, A. Gella, L. Monjas et al., "Multipotent, permeable drug ASS234 inhibits Aα aggregation, possesses antioxidant properties and protects from Aα-induced apoptosis in vitro," Current Alzheimer Research, vol. 10, no. 8, pp. 797-808, 2013.
183. A. Bacsi, M. Woodberry, M. L. Kruzel, and I. Boldogh, "Colostrinin delays the onset of proliferative senescence of diploidmurine fibroblast cells," Neuropeptides, vol. 41, no. 2, pp. 93-101, 2007.
184. Y.-F. Chu, W.-H. Chang, R. M. Black et al., "Crude caffeine reduces memory impairment and amyloid α 1-42 levels in an Alzheimer's mouse model," Food Chemistry, vol. 135, no. 3, pp. 2095-2102, 2012.
185. H. Du, L. Guo, F. Fang et al., "Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease," Nature Medicine, vol. 14, no. 10, pp. 1097-1105, 2008.
186. M. A. Ansari, G. Joshi, Q. Huang et al., "In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: Relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders," Free Radical Biology andMedicine, vol. 41, no. 11, pp. 1694-1703, 2006.
187. B. Sheng, K. Gong,Y.Niu et al., "Inhibition of α-secretase activity reduces Aα production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease," Free Radical Biology and Medicine, vol. 46, no. 10, pp. 1362-1375, 2009.
188. S. O. Bachurin, E. P. Shevtsova, E. G. Kireeva, G. F. Oxenkrug, and S. O. Sablin, "Mitochondria as a target for neurotoxins and neuroprotective agents," Annals of the New York Academy of Sciences, vol. 993, pp. 334-344, 2003.
189. J.-H. Jang, O. I. Aruoma, L.-S. Jen, H. Y. Chung, and Y.-J. Surh, "Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death," Free Radical Biology andMedicine, vol. 36, no. 3, pp. 288-299, 2004.
190. T. Vargas, D. Antequera, C. Ugalde, C. Spuch, and E. Carro, "Gelsolin restores A beta-induced alterations in choroid plexus epithelium," Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 805405, 7 pages, 2010.
191. C. Kairane, R. Mahlapuu, K. Ehrlich, M. Zilmer, and U. Soomets, "The effects of different antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains," Current Alzheimer Research, vol. 11, no. 1, pp. 79-85, 2014.
192. T. Ma, X. Du, J. E. Pick, G. Sui, M. Brownlee, and E. Klann, "Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's diseasemodel mice," Journal of Neuroscience, vol. 32, no. 40, pp. 13701-13708, 2012.
193. S.Medina, M.Martínez, and A. Hernanz, "Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and betaamyloid peptide 1-42," Free Radical Research, vol. 36, no. 11, pp. 1179-1184, 2002.
194. X. Meng, M. Wang, G. Sun et al., "Attenuation of Aα25-35- induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathways," Toxicology and Applied Pharmacology, vol. 279, no. 1, pp. 63-75, 2014.
195. H. Kawada, K. Blessing, T. Kiyota, T. Woolman, L. Winchester, and P. F. Kador, "Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-α metal dyshomeostasis," Journal of Alzheimer's Disease, vol. 44, no. 1, pp. 297-307, 2015.
196. P. I. Moreira, P. L. R. Harris, X. Zhu et al., "Lipoic acid and Nacetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts," Journal of Alzheimer's Disease, vol. 12, no. 2, pp. 195-206, 2007.
197. M.-H. Jang, S.-B. Jung, M.-H. Lee et al., "Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells," Neuroscience Letters, vol. 380, no. 1-2, pp. 26-31, 2005.
198. W. Dong, F. Huang, W. Fan et al., "Differential effects of melatonin on amyloid-beta peptide 25-35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture," Journal of Pineal Research, vol. 48, no. 2, pp. 117-125, 2010.
199. A. Gharib and H. Atamna, "Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice," in Neurodegeneration: Theory, Disorders and Treatments, chapter 3, pp. 63-86, Nova Science, New York, NY, USA, 2010.
200. M. Manczak, P. Mao, M. J. Calkins et al., "Mitochondriatargeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons," Journal of Alzheimer's Disease, vol. 20, no. 2, pp. S609-S631, 2010.
201. L. F. Ng, J. Gruber, I. K. Cheah et al., "The mitochondriatargeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease," Free Radical Biology and Medicine, vol. 71, pp. 390-401, 2014.
202. R. A. S. Robinson,G. Joshi,Q.Huang et al., "Proteomic analysis of brain proteins in APP/PS-1 human double mutant knockin mice with increasing amyloid α-peptide deposition: Insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease," Proteomics, vol. 11, no. 21, pp. 4243-4256, 2012.
203. J. Ryu, H.-N. Yu, H. Cho et al., "Neuregulin-1 exerts protective effects against neurotoxicities induced by C-terminal fragments of APP via ErbB4 receptor," Journal of Pharmacological Sciences, vol. 119, no. 1, pp. 73-81, 2012.
204. E. Turunc Bayrakdar, Y. Uyanikgil, L. Kanit, E. Koylu, and A. Yalcin, "Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aα(1-42)-induced rat model ofAlzheimer's disease," Free Radical Research, vol. 48,no. 2, pp. 146-158, 2014.
205. L. Chen, R. Na, and Q. Ran, "Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline," Neurobiology of Aging, vol. 35, no. 11, pp. 2552-2561, 2014.
206. I. K. Kim,K. J. Lee, S. Rhee, S. B. Seo, and J.H. Pak, "Protective effects of peroxiredoxin 6 overexpression on amyloid α-induced apoptosis in PC12 cells," Free Radical Research, vol. 47,no. 10,pp. 836-846, 2013.
207. J. Li, G. Wang, J. Liu et al., "Puerarin attenuates amyloidbeta- induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo," European Journal of Pharmacology, vol. 649, no. 1-3, pp. 195-201, 2010.
208. H. Zhang, Y. Liu, M. Lao, Z. Ma, and X. Yi, "Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways," Experimental Gerontology, vol. 46, no. 1, pp. 30-37, 2011.
209. N. A. Abramova, D. S. Cassarino, S. M. Khan, T. W. Painter, and J. P. Bennett Jr., "Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma," Journal of Neuroscience Research, vol. 67, no. 4, pp. 494-500, 2002.
210. J. Liu, N. Chi, H. Chen et al., "Resistin protection against endogenous Aα neuronal cytotoxicity frommitochondrial pathway," Brain Research, vol. 1523, pp. 77-84, 2013.
211. M. J. Calkins, M. Manczak, P. Mao, U. Shirendeb, and P. H. Reddy, "Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease," Human Molecular Genetics, vol. 20, no. 23, pp. 4515-4529, 2011.
212. A. Khan, K.Vaibhav, H. Javed et al., "Attenuation ofAα-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress," Molecular and Cellular Biochemistry, vol. 369, no. 1-2, pp. 55-65, 2012.
213. A. H. Alhebshi, M. Gotoh, and I. Suzuki, "Thymoquinone protects cultured rat primary neurons against amyloid α- induced neurotoxicity," Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 362-367, 2013.
214. C.-W. Chi, Y.-L. Lin, Y.-H. Wang, C.-F. Chen, C.-N. Wang, and Y.-J. Shiao, "Tournefolic acid B attenuates amyloid α protein-mediated toxicity by abrogating the calciumoverload in mitochondria and retarding the caspase 8-truncated Bid-cytochrome c pathway in rat cortical neurons," European Journal of Pharmacology, vol. 586, no. 1-3, pp. 35-43, 2008.
215. S. H. Lee, K. R. Kim, S. Y. Ryu et al., "Impaired short-term plasticity in mossy fiber synapses caused by mitochondrial dysfunction of dentate granule cells is the earliest synaptic deficit in a mouse model of Alzheimer's disease," The Journal of Neuroscience, vol. 32, no. 17, pp. 5953-5963, 2012.
216. S.-Y. Kook, K.-M. Lee, Y. Kim et al., "High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice," Cell Death and Disease, vol. 5, no. 2,Article ID e1083, 2014.
217. M. J. Santos, R. A. Quintanilla, A. Toro et al., "Peroxisomal proliferation protects from α-amyloid neurodegeneration," The Journal of Biological Chemistry, vol. 280, no. 49, pp. 41057-41068, 2005.
218. M. Montinaro, D. Uberti, G. MacCarinelli, S. A. Bonini, G. Ferrari-Toninelli, and M. Memo, "Dietary zeolite supplementation reduces oxidative damage and plaque generation in the brain of an Alzheimer's diseasemouse model," Life Sciences, vol. 92, no. 17-19, pp. 903-910, 2013.
219. P. I. Moreira, S. M. Cardoso, C. M. Pereira, M. S. Santos, and C. R. Oliveira, "Mitochondria as a therapeutic target in Alzheimer's disease and diabetes," CNS and Neurological Disorders-Drug Targets, vol. 8, no. 6, pp. 492-511, 2009.
220. R. A. J. Smith, G. F. Kelso, A. M. James, and M. P. Murphy, "Targeting coenzyme Q derivatives to mitochondria," Methods in Enzymology, vol. 382, pp. 45-67, 2004.
221. C. Lu, D. Zhang, M. Whiteman, and J. S. Armstrong, "Is antioxidant potential of themitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA?" Antioxidants and Redox Signaling, vol. 10, no. 3, pp. 651-660, 2008.
222. H. H. Szeto, "Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents," The AAPS Journal, vol. 8, no. 3, pp. 521-531, 2006.
223. N. Xie, C. Wang, Y. Lian, C. Wu, H. Zhang, and Q. Zhang, "Inhibition of mitochondrial fission attenuates Aα-induced microglia apoptosis," Neuroscience, vol. 256, pp. 36-42, 2014.
224. C. Y. Ye, Y. Lei, X. C. Tang, andH. Y. Zhang, "Donepezil attenuates Aα-associated mitochondrial dysfunction and reduces mitochondrial Aα accumulation in vivo and in vitro," Neuropharmacology, vol. 95, pp. 29-36, 2015.
225. S. D. Rege, T. Geetha, G. D. Griffin, T. L. Broderick, and J. R. Babu, "Neuroprotective effects of resveratrol in Alzheimer disease pathology," Frontiers inAgingNeuroscience, vol. 6, article 218, 2014.
226. A. Jelenkovíc, M. D. Jovanovíc, I. Stevanovíc et al., "Influence of the green tea leaf extract on neurotoxicity of aluminium chloride in rats," Phytotherapy Research, vol. 28, no. 1, pp. 82-87, 2014.